Why was the cohort consortium set up?
Chronic kidney disease (CKD) is defined as reduced glomerular filtration rate (GFR) or kidney damage (usually represented by albuminuria) and is a major global public health problem. CKD affects 10 to 16% of the adult population in Asia, Australia, Europe and North America, [1] [2] [3] [4] [5] [6] and increases the risk of premature mortality, cardiovascular disease and kidney failure. [7] [8] [9] [10] Studies investigating the clinical impact of CKD have obtained conflicting results, often owing to different analytic strategies, leaving uncertainties in CKD definition, staging and management.
Non-linear association of kidney function with outcomes make uniform analysis particularly important because reference groups including elevated risk in different cohorts spanning different parts of a U-shaped association can lead to apparent differences where none might exist. Needing to explore non-linearity, multiple factors and interaction further increased the need for both sophistication and uniformity in comparing analyses across cohorts and pooling data to maximize power and examine consistency of associations. A comprehensive examination with data from around the world, a uniform analytic plan and standardized kidney disease measures [both estimated GFR (eGFR) and albuminuria] were needed to provide a solid foundation to optimize prevention and management of CKD. This need was the impetus for the establishment of the Chronic Kidney Disease Prognosis Consortium (CKD-PC).
CKD-PC was first established at a collaborators meeting held in London in October of 2009 with the support of the Kidney Disease: Improving Global Outcomes (KDIGO) organization and the US National Kidney Foundation (NKF). More than 100 investigators, representing 450 cohorts worldwide, participated and discussed approaches to improve the definition and staging of CKD. KDIGO, NKF and the participants were enthusiastic about extending this meta-analysis exercise into a consortium to address critical questions related to CKD prognosis.
An NKF grant currently funds the CKD-PC Data Coordinating Center at Johns Hopkins University in Baltimore, MD, USA. This supports the operation of the Consortium and limited time of investigators and staff at the Data Coordinating Center. Currently, a few pharmaceutical companies (Abbott, Amgen and Merck) support CKD-PC directly or indirectly (through NKF). Established mechanisms of support for data collection within participating cohorts are acknowledged elsewhere. [11] [12] [13] [14] Who is in the cohort consortium?
Details about study selection were previously published. 7, 15 Briefly, studies were initially found through a literature search in 2009 on PubMed using keywords such as eGFR, albuminuria, mortality and end-stage renal disease (ESRD). The search was expanded by reviewing the references from articles retrieved, as well as communication between collaborators and experts. Principal investigators of selected studies were invited to participate. A few cohorts joined the Consortium in 2011 and 2012.
CKD-PC includes three types of cohorts in terms of source population, general population cohorts, high-risk cohorts selecting subjects at high cardiovascular risk (such as hypertension or diabetes) and CKD cohorts specifically enrolling subjects with CKD. A 'cohort' is taken to be any study with follow-up data, including randomized controlled trials. To be included in the CKD-PC meta-analyses, the cohort has to have information at baseline on eGFR and albuminuria, at least 1000 participants (except for CKD cohorts) and at least one outcome of interest (listed subsequently) with a minimum of 50 events. [7] [8] [9] [10] [11] [12] [13] [14] The Consortium currently consists of 46 cohorts with data on 2.1 million participants from 40 countries in Asia, Europe, North and South America and Australasia (Figure 1 ). These 46 cohorts consist of 26 general population cohorts, 7 high-risk cohorts and 13 CKD cohorts (Table 1) . [11] [12] [13] [14] Study names and collaborators are given in the acknowledgements.
How often have they been followed up?
CKD-PC has been working on groups of topics in 1-to 2-year cycles (up to now: phase 1, 2009-11 and phase 2, 2011-12) and asks collaborating cohorts to compile data for each phase. All CKD-PC collaborating cohorts contribute data; however, each cohort can decide to opt in/ out for each topic at initiation of the analysis. The mean follow-up is 5.8 years across the 46 cohorts (a total of 12 million person-years) participating in phase 2.
What has been measured?
Baseline kidney measures eGFR is assessed for serum creatinine 16, 17 and/or cystatin C 18 using various GFR estimation equations. Standardization of serum creatinine or cystatin C is not uniform in all cohorts, but all are able to provide details on collection/measurement methods to allow for calibration. Also, we conduct sensitivity analyses to assess whether lack of standardization in some studies influences our estimates. 11 As recommended in clinical guidelines, 2, 19 urine albumin-to-creatinine ratio is the preferred measure of albuminuria; however, urine albumin excretion rate, urine protein-tocreatinine ratio and using dipstick as an ordinal measure are accepted. Particular attention is paid to evaluating the eGFR and albuminuria thresholds for the definition and staging of CKD.
Baseline covariates
Data on the following potential confounders of the association between kidney measures and outcomes are obtained, when available within the cohort: age, sex, race/ethnicity, smoking, history of cardiovascular disease, lipids, diabetes mellitus, fasting glucose levels, hypertension status, blood pressure and body mass index. Information on use of medications for hypercholesterolaemia, diabetes and hypertension is also collected, when available within the cohort. Methods used to measure these covariates are not necessarily uniform, and each study provides details whenever they deviated from the standard definitions.
Outcome variables
Outcomes of interest in phases 1 and 2 are all-cause mortality, cardiovascular mortality (death owing to myocardial infarction, sudden cardiac death, heart failure, stroke), ESRD (initiation of dialysis, kidney transplantation, death coded owing to kidney disease), acute kidney injury (ICD-9 code 584 or ICD-10 code N17) and progression of CKD (decline in eGFR to <45 ml/min/1.73m 2 , with an average annual rate of eGFR decline of 52.5 ml/min/ 1.73m
2 ). [7] [8] [9] [10] Looking at a broad range of outcomes is important because associations have subtle differences, particularly across the full age span (e.g. higher risk of mortality but lower risk of ESRD as age increases). 20 The consortium encourages and provides expertise to facilitate cohorts adding relevant outcomes, particularly acute kidney injury and ESRD.
What has it found? Key findings and publications
During phase 1 (2009-11) , CKD-PC focused on the associations of eGFR and albuminuria with the aforementioned clinical outcomes, resulting in the publication of four meta-analyses, [7] [8] [9] [10] and enabled achievement of an international consensus on the definition and staging of CKD described in the KDIGO conference summary. 15 These articles quantified the global impact of low eGFR and high albuminuria on mortality and kidney outcomes in general, 7, 8 high-risk 8, 9 and CKD 10 populations. Key findings of these articles were as follows ( Figure 2 ): (i) the full range of GFR and albuminuria contributes to increased risk; (ii) low eGFR and high albuminuria confer clinical risk independently of each other and traditional risk factors; (iii) the results were largely consistent across populations and regions. [7] [8] [9] [10] These results confirmed the threshold values in current use for the definition of CKD and provided insights into additional thresholds that could be used for staging. Thus, Consortium results provided basic data to inform a KDIGO-independent committee tasked to update CKD definition and staging. 21 CKD-PC phase 2 (2011-12) focuses on the evaluation of the impact of new eGFR equations on risk categorization, as well as the assessment of the relationship of eGFR and albuminuria across a range of subgroups to assess potential effect modification by age, sex, race/ethnicity, or hypertension or diabetes status. At the time of writing, the first three of the seven proposed phase 2 articles have been published. 11, 13, 14 The first phase 2 article showed the superiority of the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation creatinine equation to the Modification of Diet in Renal Disease Study equation, an equation broadly used in clinical practice, in terms of risk prediction. 11 The second and third articles examined the effect modification of kidney measures with hypertension and diabetes, respectively. The article focusing on hypertension showed that lower eGFR and higher albuminuria were more strongly associated with mortality among those without hypertension vs those with, but the associations were similar for ESRD. 13 The article focusing on diabetes showed higher risks for mortality and ESRD in diabetes compared with non-diabetes in the entire range of eGFR and albuminuria, but the relative risks by eGFR and albuminuria were similar regardless of diabetes status.
14 Both these articles support consideration of CKD as at least an equally relevant risk factor despite hypertension or diabetes status. The other four articles, one focusing on the impact of eGFR equations using cystatin C and three evaluating the separate effect modification on eGFR and albuminuria with age, sex or race/ethnicity are in various stages of writing. At the 2011 American Society of Nephrology Kidney Week, the CKD-PC presented abstracts describing the Consortium's approach to meta-analysing individual participant data, 22 Figure 1 Countries (shaded) with at least one participant in CKD-PC collaborating cohorts Table 1 Characteristics of cohorts included in phase 2 analysis comparison of eGFR equations 23 and evaluation of interaction in meta-analyses using our model of distributed analyses. 24 The Consortium continues to work on more sophisticated analyses (e.g. risk prediction and time-varying covariates).
What are the main strengths and weaknesses?
To the best of our knowledge, this is the largest open consortium in kidney disease research, with data on eGFR and albuminuria from 52 million individuals, providing statistical power to conduct complex meta-analyses (e.g. pooling splines). The collaborating cohorts include participants from four continents representing general, high-risk and CKD populations. This broad range of populations enables evaluation of the consistency of results and thus provides greater generalizability of Consortium findings.
Expert collaborators in our consortium include nephrologists, internists, endocrinologists, cardiologists, epidemiologists and biostatisticians from around the globe. The diverse backgrounds of the members facilitate choosing the topics most relevant to clinical practice and public health, conducting state of the art statistical analyses, publishing relevant articles in high impact journals and disseminating our findings to a broad range of audiences. Collaborators have the opportunity to take on roles in the governance/operation (the Steering Committee) and analyses/manuscripts (Writing Committees), meeting periodically via web conferencing. The Consortium provides an example of a new highly collaborative model in epidemiological research. Figure 2 Summary of categorical meta-analysis [adjusted relative risk (RR)] for general population cohorts with albumin-to-creatinine ratio (ACR). 15 Mortality is reported for general population cohorts assessing albuminuria as urine ACR. Kidney outcomes are reported for general population cohorts assessing albuminuria as either urine ACR or dipstick. Estimated glomerular filtration rate (eGFR) and albuminuria are expressed as categorical variables. All results are adjusted for covariates and compared with the reference cell (Ref) . Each cell represents a pooled relative risk from a meta-analysis; bold numbers indicate statistical significance at P < 0.05. Incidence rates per 1000 person-years for the reference cells are 7.0 for all-cause mortality, 4.5 for cardiovascular disease mortality, 0.04 for kidney failure, 0.98 for acute kidney injury (AKI) and 2.02 for kidney disease progression. Absolute risk can be computed by multiplying the relative risks in each cell by the incidence rate in the reference cell. Colours reflect the ranking of adjusted relative risk. The point estimates for each cell were ranked from 1 to 28 (the lowest RR having rank number 1, and the highest number 28). The categories with rank numbers 1-8 are green, rank numbers 9-14 are yellow, the rank numbers 15-21 are orange and the rank numbers 22-28 are coloured red. (For the outcome of kidney disease progression, two cells with RR < 1.0 are also green, leaving fewer cells as orange.)
Uniform definitions of exposures, outcomes and covariates enable evaluation of heterogeneity across cohorts in an objective manner across a wide range of geographical, demographical and clinical settings. Many cohorts are able to provide individual participant level data to the Data Coordinating Center, allowing more analytic options. Cohorts that cannot provide individual level data run statistical code created by the Data Coordinating Center and send the analysed outputs (e.g. variance-covariance matrices) for meta-analysis. The distributed model maximizes the number of participating cohorts by allowing inclusion of cohorts that cannot release individual level data, often for structural reasons (e.g. contract with a government or sponsors).
There are limitations of the Consortium. Methods of data collection are not standardized a priori across cohorts, although collaboration has increased uniformity of definitions and statistical comparisons for standardization as compared with meta-analysis using published results. Races/ethnicities other than Whites, Asians and Blacks are underrepresented within the Consortium. Moreover, Blacks mainly come from US cohorts, and Asians are predominantly Eastern Asian. Novel biomarkers may not be available across collaborating cohorts. For cohorts that cannot send individual level data, the complete statistical analysis, including all contingencies, needs to be planned in advance because the number of requests for analyses to the cohort needs to be very limited. Most analyses can be done in two stages (within cohort and then pooled), but models that require fitting all the individual data can only be run on data that were shared with the Data Coordinating Center. Finally, with Steering Committee members and collaborators from the west coast of Canada to Australia, the timings of our web meetings can be a challenge.
This Consortium approach differs from traditional meta-analysis reliance on comprehensive literature searches. Validity is maximized by conducting a random-effects meta-analysis which models both within and between study variability among leading cohorts of all types. Publication bias is avoided by having cohorts opt in early based on data availability and willingness to collaborate without knowing the results of the analysis. However, the need for active collaboration means that it is impractical to have every cohort that may have data or publish on a given topic. On the other hand, there is substantial gain in analysing cohorts that may not have prioritized publishing on CKD using a rigorously planned uniform analysis.
Can I get hold of the data? Where can I find out more?
CKD-PC has agreed with collaborating cohorts not to share data outside the Consortium. Each participating cohort has its own policy for data sharing. CKD-PC is open to the inclusion of more cohorts, as well as suggestions for articles and reports. Further details on CKD-PC, including information for joining and a full list of publications, are available from the website: www.jhsph.edu/ckdpc. This website also includes Stata and SAS code to run the analyses presented in some of our articles.
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